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Aim. This paper aimed to examine the chemoprotective actions of aqueous black tea extract (BTE) against nonalcoholic
steatohepatitis- (NASH-) induced skeletal changes in rats. Material. Wistar rats (body wt. 155–175g) of both sexes, aged 4–5
months, were randomly assigned to 3 groups; Group A (control), Group B (60% high-fat diet; HFD), and Group C (HFD + 2.5%
BTE). Methods. Several urinary (calcium, phosphate, creatinine, and calcium-to-creatinine ratio) serum (alkaline phosphatase
and serum tartrate-resistant acid phosphatase), and molecular markers of bone turnover (receptor activator of NF-κB ligand
(RANKL), osteoprotegerin (OPG), and estrogen) were tested. Also, several bone parameters (bone density, bone tensile strength,
bone mineral content, and bone histology) and calcium homeostasis were checked. Results. Results indicated that HFD-induced
alterations in urinary, serum, and bone parameters as well as calcium homeostasis, all could be signiﬁcantly ameliorated by BTE
supplementation. Conclusion. Results suggest a potential role of BTE as a protective agent against NASH-induced changes in bone
metabolism in rats.
1.Introduction
Nonalcoholic steatohepatitis (NASH) is a condition, which is
described as accumulation of fat in liver with inﬂammation.
This disorder may be observed in patients with no history of
signiﬁcant alcohol consumption, though histological exami-
nation may resemble alcohol-induced liver injury. It indeed
may be the ﬁrst clinical indication of insulin resistance,
with complication of high blood pressure, coronary heart
disease (CHD), and type 2 diabetes [1, 2]. It is claimed
that, after cancer, cirrhosis from NASH is now the second
most common age-related cause of death in type II diabetes
[3]. Similar alarming observation is the association between
human bone diseases with liver diseases, like viral liver
cirrhosis is a risk factor for increased loss of minerals from
bone [4, 5]. In an identical manner, patients with cholestatic
liver disease have low bone turnover [6]. Even earlier [7, 8],
it was reported that hepatic diseases are frequently associated
with metabolic bone disorders. Hepatic osteodystrophy was
reported to occur in up to 50% of patients with chronic
liver disease (CLD). The results of this report suggested
that increased bone resorption and less bone formation
are the predominant cause of hepatic osteodystrophy in
patients with CLD [9]. Osteopenia and osteoporosis are
common complications of chronic liver disease. Patients
with chronic liver disease may have other complications,
such as malnutrition, loss of muscle mass, hypogonadism,
low calcium intake, and vitamin D deﬁciency, all of which
alter normal bone metabolism [10]. Several earlier studies
had indicated the possible role of lipids in osteoporosis.
High lipid levels were found closely related with decrease in
bonemineraldensity(BMD)coupledwithosteoporosis[11–
13] as well as other disorders that may be a consequence
of high lipids, including cardiovascular calciﬁcation [14–
16] and atherosclerosis [11]. Consistent with these ﬁndings
are the results of two in vivo studies that have shown2 Journal of Osteoporosis
that mice [17] and chickens [18] fed on a high-fat, high-
cholesterol diet have reduced bone mineral density. An
earlier study also had indicated that diets with high saturated
fat content can produce deleterious eﬀects on the absorption
of dietary calcium and consequently an adverse eﬀect on
bone mineralization in growing animals [19]. Perhaps even
more signiﬁcant are data reporting that the loss in bone
mineral density by high lipid diet can be revived with
antioxidants, suggesting a possible mechanism of action
through suppression of lipid oxidation levels [18].
Tea (Camellia sinensis) is rich in polyphenolic com-
pounds, collectively known as the tea ﬂavonoids. Its
therapeutic value come forefront with numerous reports
on tea as antioxidants, hypolipidemic, antineoplastic, and
hypocholesterolemic [20–23]. Tea also has been reported
to possess a cardiovascular-protective eﬀect [24, 25]. In an
epidemiological report it has been suggested that skeletal
health is better preserved in aged women who drank tea than
nontea drinkers [26]. Similar epidemiological studies have
conﬁrmed that tea drinking may be a possible preventive
measure to reduce risk of bone loss in postmenopausal
women as well as in men by increasing BMD [27, 28].
Estrogenic activity of naturally occurring isoﬂavones by
virtue of their ability to bind nuclear estrogen receptor was
reported earlier [29], and, recently, soy isoﬂavones with weak
estrogen-like activities have been reported to modulate bone
metabolism and serum lipids in perimenopausal women
[30]. A recent study has further indicated that soy isoﬂavone
can reduce the risk of obesity and preserve bone health
in menopausal women [31]. Moderate consumption of tea,
which contains ﬂavonoids closely related to soy isoﬂavones,
has been reported to be associated with higher BMD in
men and women [26, 27] and lower rates of fracture [32,
33]. Results of series of studies from our laboratory with
aqueous black tea extract [34–36] further support the idea
that phytocompounds have eﬃcacy in preventing bone loss.
This study aimed to examine the protective role of black tea
extract (BTE) against nonalcoholic steatohepatitis- (NASH-)
induced skeletal dysfunction.
2. Methods
2.1. Animals. As NASH does not have any gender speciﬁcity
a n di ss e e ni nb o t hs e x e s ,a n i m a l sf r o mb o t hs e x e sw e r e
selected for this study. Wistar rats, both male and female,
aged 4-5 months, weighing 155–170g were procured from a
local authorized breeder registered under the Committee for
the Purpose of Control and Supervision of Experiments on
Animals (CPCSEA), Ministry of Environment and Forests,
Government of India. Upon arrival at our institute, all
animals were kept under standard conditions (12 hours
light/dark schedule and at 25 ±2◦Cr o o mt e m p e r a t u r e
throughout the experimental period) for a week with free
access to drinking water and standard laboratory diet com-
posed of 71% carbohydrate, 18% protein, 7% fat, and 4%
salt mixture [37]. All animal experiments were performed
according to the ethical guidelines suggested by the Institu-
tional Animal Ethics Committee (IAEC) and Committee for
the Purpose of Control and Supervision of Experiments on
Animals (CPCSEA), Ministry of Environment and Forests,
Government of India.
2.2. Diet and Treatment. Eighteen animals were randomly
assigned to three groups: Group A (regular diet), Group B
(high-fat diet), and Group C (high-fat diet + BTE). Each
group contained six animals, three male and three female.
Group A animals were fed standard laboratory diet [37]
containing 71% carbohydrate, 18% protein, 7% fat, and 4%
salt mixture. Group B animals were fed high-fat diet [38]
containing carbohydrate: 22%, fat: 60% containing corn oil
(palmitic acid: 6.3–18.2%, stearic acid: 0.9–4.5%, oleic acid:
18.5–46.1%, linoleic acid: 36.6–66.8%, linolenic acid: 0–
2%, and arachidonic acid: 0–1.4%) [39], and protein: 18%.
Animals of group C, in addition to high fat diet, were fed
2.5% (25g/L) BTE by gavage technique for 30 days at a single
dose of 10mL/kg/day [40]. Animals of group A and B were
given deionized water by gavage technique, 10mL/kg/day as
vehicle. In our preliminary studies, a fourth group (Group
D) of animals was included containing six animals (male
3, female 3), which were given standard laboratory diet
simultaneously with 2.5% BTE by gavage technique for 30
days at a single dose of 10mL/kg/day. As aqueous black tea
extractinGroupDanimalsindependentlycouldnotproduce
any signiﬁcant variation of results in marker parameters of
NASH, compared to control, this group was not considered
for further detailed study to restrict animal use as per
recommendation of the Animal Ethics Committee.
2.3. Preparation of Aqueous BTE. The black tea (Camellia
sinensis) extract was prepared from CTC (Curl, Tear and
Crush) BOP- (Broken Orange Pickoe-) grade black clonal
tea. It was processed and supplied by Tocklai Experimental
Station, Jorhat, Assam, India to the Drug Development Divi-
sion,IndianInstituteofChemicalBiology,Jadavpur,Kolkata,
India. We received a generous gift from that institute. A
fresh 2.5% aqueous BTE was prepared everyday following
the method of Wei et al. [40]. Twenty-ﬁve gram of black tea
was added to 500mL of boiling water and was steeped for
15min. The infusion was cooled to room temperature and
thenﬁltered.Thetealeaveswereextractedasecondtimewith
500mL of boiling water and ﬁltered, and the two ﬁltrates
were combined to obtain a 2.5% aqueous black tea extract
(2.5g of tea leaf/100mL water). The resulting clear solution
is similar to tea brews consumed by humans.
2.4. Selection of Eﬀe c t i v eD o s eo fH i g hF a tD i e ta n dB l a c k
Tea Extract. For determination of eﬀective dose (ED) of
high fat diet (HFD) and black tea extract (BTE), dose
response studies were undertaken. In case of high fat, it was
observed that although signiﬁcant changes could be seen
from 30% of high fat onward, but both biochemical and
histological changes were most prominent with 60% HFD.
Similar changes with 60% HFD were reported earlier [38].
As for BTE, a submaximal dose response study revealed that
signiﬁcant recovery responses were seen with doses betweenJournal of Osteoporosis 3
2-3% (w/v) aqueous BTE. Recovery responses with similar
dose of BTE were also reported earlier [40].
2.5. Urine Collection. Fasting urine was collected for 24
hours (9AM to next day 9AM) according to the standard
laboratory procedure [41] as described elsewhere by Chanda
et al. [37]. Care was taken so that no urine was lost through
evaporation. Total volume of urine was measured, and the
following parameters were assessed.
2.6. Estimation of Urinary Parameters
2.6.1. Urinary Calcium. Urinary calcium was measured
according to the method of Adeniyi et al. [42]. The assay
of calcium was based on the principle that metal com-
plexing dye orthocresopthalein complexone (CPC) forms
a chromophore with calcium in alkaline solution. Diethy-
lamine (DEA) were added to enhance the colour intensity.
For urinary calcium estimation, to 20μL of urine 1mL
CPC reagent and 1mL DEA buﬀer was added. Colour
intensity was measured at 575nm against a blank by using
a UV-double beam spectrophotometer (Shimadzu 160A;
Shimadzu Corporation, Kyoto, Japan). Calcium carbonate
(CaCO3) solution pH-3.0 was used as standard. All the
reagents were prepared with calcium-free triple distilled
water.
2.6.2. Urinary Phosphate. Urinary phosphate was measured
according to the method of Lowry and Lopez [43]. For
urinary phosphate estimation, 10μL of urine was diluted 50
times with distilled water and to it 1mL molybdate reagent
and200μLaminonaphtholsulfonicacid(ANSA)wasadded,
mixed well, and kept in dark for 10 minutes. Reading
was taken at 630nm against blank. The concentration of
phosphate in urine was calculated using a standard curve of
monopotassium phosphate (KH2PO4).
2.6.3. Urinary Creatinine. Urinary creatinine was measured
according to the method of R. L. Nath and R. K. Nath
[44]. For urinary creatinine estimation, 50μL of urine was
diluted 10 times and to it 2mL saturated picric acid and
150μL 10% sodium hydroxide solution were added, mixed
and kept for 15 minutes at 37◦C incubator. To it, 5mL of
water was added. Reading was taken at 520nm against blank.
Theconcentrationofcreatinineinurinewascalculatedusing
a standard curve of creatinine.
2.7. Serum Collection. Blood was collected directly from the
heart under urethane anesthesia (1.7mg/g body weight).
Serum was obtained by using standard laboratory protocol.
2.8. Estimation of Serum Alkaline Phosphatase (AP) Activ-
ity. Serum alkaline phosphatase was measured using p-
nitrophenyl phosphate as substrate [45]. Alkaline phos-
phatase activity was measured by the hydrolysis of p-
NPP (paranitrophenyl phosphate) at pH-10.8 using glycine-
NaOH buﬀer at 37◦C. In brief, 0.5mL of 5.5mM p-NPP
in 0.4mL of glycine-NaOH buﬀer (pH-10.8) solution were
pipetted in a test tube and incubated at 37◦Cf o r1 0m i n u t e s .
After incubation, 0.05mL of sample was added, mixed, and
incubated at 37◦C for 30 minutes. Reaction was stopped
by adding 4mL of 0.1N NaOH, and reading was taken at
410nm against a blank in a spectrophotometer (Shimadzu
160A; Shimadzu Corporation, Kyoto, Japan).
2.9. Estimation of Serum Tartrate-Resistant Acid Phosphatase
(TRAP) Activity. Serum TRAP activity was estimated by
kinetic methodbyusingreagentkit(LABKIT,Spain).Brieﬂy,
unhemolyzed serum was mixed with the test reagent (10mM
α-naphthyl phosphate, 6mM Fast Red TR, and 2mM
sodium tartrate in 50mM sodium citrate buﬀer, pH-5.2)
and the absorbance of the sample was read at 405nm at
1 minute interval thereafter for 3 minutes. The diﬀerence
of absorbance and the average absorbance diﬀerence per
minute (ΔA/min) was calculated [46].
2.10. Estimation of Serum Estradiol. Serum was obtained
by using standard laboratory protocol. Serum estrogen
level (pg/mL) was determined by using the ELISA EIAgen
Estradiolkit(AdaltisItalia,Italy).Allsampleswereassayedin
duplicate. The intra-assay coeﬃcient of variation was 9.08%.
To avoid inter-assay variation all samples were run at one
time.
2.11. Estimation of Serum RANKL. Serum RANKL was
estimated by using the ELISA kits (Quantikine, R & D
Systems Inc., Minneapolis, MN, USA). All samples were
assayed in duplicate. The intra-assay variation was 11.75%.
All samples were run at one time to avoid inter-assay
variation. Optical density of each well was determined by
using a microplate reader (Thermo Labsystems, Finland).
2.12. Estimation of Serum Osteoprotegerin (OPG). Serum
OPG was estimated by using the ELISA kits (Quantikine,
R & D Systems Inc., Minneapolis, MN, USA). All samples
were assayed in duplicate. The intra-assay variation was
10.09%. All samples were run at one time to avoid inter-
assay variation. Optical density of each well was determined
by using a microplate reader (Thermo Labsystems, Finland).
2.13. Measurement of Bone Density. The right femur, eighth
thoracic rib, eighth thoracic vertebra, and fourth lumbar
vertebra were freed oﬀ soft tissue and cleaned using small
scissors, tweezers, and cotton gauze. Before measurement
of the density, femur was cut at the middiaphysis and
the marrow was washed out. Bone density was measured
according to the method described by Arjmandi et al. [47]
by using Archimedes’ principle. Brieﬂy, each bone was put in
an unstoppered vial ﬁlled with deionized water, and the vial
was placed under a vacuum for 90 minutes to ensure that
all the trapped air diﬀused out of the bone. Each bone was
removed from the vial, blotted with gauze sponge, weighed,
and returned to the vial containing deionized water. The
bone was reweighed in water and density was calculated
(g/cm3 bone volume).4 Journal of Osteoporosis
2.14. Estimation of Bone Tensile Strength. After sacriﬁce of
the animal, left femur was excised and cleaned oﬀ adhering
soft tissues. Bone tensile strength was measured as described
by Shapiro and Heaney [48] using a hand-held force meter
(Excel Enterprises, India). Brieﬂy, the femur was supported
latitudinally on each end, and pressure was placed directly
onto the middle of the bone until it fractured. The breaking
force (kg) was recorded.
2.15. Estimation of Bone Calcium and Bone Phosphate Level.
Right femur, eighth thoracic rib, eighth thoracic vertebra,
and fourth lumbar vertebra were removed and cleaned of
adhering tissue. The whole bone was extracted two times
with a 1:1 mixture of ethanol and diethyl ether for 48
hours and one time with diethyl ether for 24 hours. The
dehydratedanddefattedboneswereturnedintoashat600◦C
for 48 hours and hydrolyzed in 6N HCl for determination of
calcium and phosphate [49]. Calcium and phosphate were
estimated according to the method as described, respectively,
by Adeniyi et al. [42] and Lowry and Lopez [43].
2.16. Preparation of Intestinal Loops. After the experimental
period was over, the animals of all groups were fasted for
16 hours. The preparation of animals and intestinal loops
for the study of calcium transference in situ was made
by following the method as described elsewhere by Islam
et al. [50]. Brieﬂy, the animal was anesthetized (urethane,
1.7mg/kg body weight), the abdomen of each animal was
openedthroughamidlinelongitudinalincision,thebileduct
was ligated and duodenal, jejunal, and ileal segments were
located. Two ligatures, one proximal and the other distal,
were applied tightly in each loop measuring about 8cm in all
duodenal, jejunal, and ileal segments. Loops were so selected
that each contained 8–10 vessels, and care was taken so that
no major blood vessels were occluded by the ligature.
2.17. Measurement of Intestinal Calcium Transference. For
the measurement of intestinal calcium transference, 1mL
of prewarmed (37◦C) Tris-HCl buﬀer solution containing
0.2mM CaCl2 was injected with a 25-gauge needle in each
ligated segment. The intestinal loops were placed in their
usual position and the abdomen was closed. After one hour,
animals were sacriﬁced, the preselected loops were removed
and the ﬂuid from each loop was collected separately,
together with a few washings of the lumen with triple
distilled water. The collected ﬂuid was then increased to a
deﬁnite volume with calcium free triple distilled water. A
fraction of this ﬂuid was then used for the estimation of Ca2+
using a double beam spectrophotometer (Shimadzu, UV-
160A) according to the method described by Adeniyi et al.
[42]. The diﬀerence between the amount of Ca2+ introduced
and the amount left unabsorbed was used to estimate the
amount of Ca2+ absorbed. The intestinal part constituting
the loop was dried on a watch glass in an electric oven at
90◦C to attain a constant weight, which was recorded as the
weight of the dried loop. Intestinal transference of calcium
was expressed as μM of calcium/g of dry weight/hour.
2.18. Preparation of Intestinal Mucosal Extract. After sacriﬁc-
ing the animal and opening of the abdomen, the whole of the
small intestine was quickly removed. The portion comprised
of the duodenum, jejunum, and ileum were separated and
chilled in ice. Intestinal mucosa was collected as described
by Maenz and Cheeseman [51], and the scrapings were
homogenized according to the method of Koyama et al. [52].
2.19. Estimation of Intestinal Mucosal Alkaline Phosphatase
Activity. The activity of alkaline phosphatase of intestinal
mucosa was estimated by using p-nitrophenyl phosphate as
substrate [45]. The protein content of the homogenate used
for the study was determined using the method of Lowry et
al. [53].
2.20. Estimation of Intestinal Mucosal Ca2+ Activated ATPase
Activity. The activity of the enzyme Ca2+-ATPase was also
studied from the mucosal extract using the method of Rorive
and Kleinzellar [54]. The assay was based on the principle
that the release of inorganic phosphate (Pi) from ATP is
measured in presence of either Ca2+ or Mg2+. For the assay
of mucosal Ca2+, activated ATPase, 250μL 0.4M Tris-HCl
buﬀerpH-7.4and250μL40mMATP(Tris-salt,Sigma)were
added into three of the test tubes placed on ice. To tubes
1 and 3, 250μLo f4 0m MC a C l 2 were added. At time zero,
the reaction was started by addition of 250μLo fm u c o s a l
homogenate to tubes 1 and 2. The volumes in all tubes were
adjusted to 2mL with calcium free distilled water. The three
tubes were then incubated at 37◦C with gentle shaking for 30
minutes. Under this condition the release of Pi is linear unto
60mins. The reaction was stopped by transfer of the tubes to
iceandadditionof0.4mLice-cold35%(w/v)trichloroacetic
acid (TCA). The tubes were then centrifuged for 10 minutes
at 10,000rpm in a refrigerated centrifuge. The protein pellet
was dissolved in 1mL of 1N sodium hydroxide (NaOH),
and protein content was determined following the method
of Lowry et al. [53]. Phosphate liberated during Ca2+ ATPase
enzyme activity was estimated by the method of Lowry and
Lopez [43].
2.21.BoneTissueCollectionandProcessing. Theleftproximal
tibia and fourth lumbar vertebra were removed, dissected
free of soft tissue, and ﬁxed with 4% paraformaldehyde for
16–18 hours at 4◦C. After ﬁxation, specimens were washed
for 12 hours at 5◦C in each of the following series of
solutions: 0.01M PBS containing 5% glycerol, 0.01M PBS
containing 10% glycerol, and 0.01M PBS containing 15%
glycerol. The specimens were then decalciﬁed in EDTA-G
solution (14.5g EDTA, 1.25g NaOH, and 15mL glycerol,
pH-7.3) for 10–14 days. The decalciﬁed tissues were washed
sequentially at 5◦C for 12 hours in (a) 15% sucrose and
15% glycerol in PBS, (b) 20% sucrose and 10% glycerol
in PBS, (c) 20% sucrose and 5% glycerol in PBS, (d) 20%
sucrose in PBS; 10% sucrose in PBS, (e) 5% sucrose in PBS,
and (f) 100% PBS. Then the tissues were washed with PBS
and dehydrated in graded series of alcohols, followed by
clearing in xylene, and ﬁnally embedded in paraﬃn[ 55].
T h es pe c i m e nw e r ec u ti n t o5 - 6μm sections and stained withJournal of Osteoporosis 5
haematoxylin-eosin. Representative sections were observed
and photomicrography was performed with the help of a
bright ﬁeld microscope equipped with a digital camera (Carl
Zeiss, Germany).
2.22. Statistical Analysis. Data were expressed as mean
± S.E.M. obtained from a particular group comprising
both male and female animals. Data were compared using
Kruskal-Wallis nonparametric ANOVA followed by Mann-
Whitney “U” multiple comparison test (software version
2.6.5, StatsDirect, UK). Diﬀerences were considered signiﬁ-
cant if P<. 05.
3. Results
3.1. Urinary Calcium, Phosphate, and Creatinine Excretion
Proﬁles and Calcium-to-Creatinine Ratio. The urinary cal-
cium, phosphate, and creatinine excretion proﬁles together
with Ca:Cr ratio of control group (Group A), HFD (Group
B), and HFD + BTE (Group C) are shown in Table 1.
Compared to control group, animals of HFD-fed group
showed a signiﬁcant increase in all the urinary parameters
studied, namely, calcium, phosphate, creatinine, and Ca:Cr
ratio (P<. 01). Elevated response of all these parameters
was signiﬁcantly counter regulated in the HFD + BTE-
s u p p l e m e n t e dg r o u po fr a t s( G r o u pC ) .
3.2. Serum Alkaline Phosphatase (AP) and Tartrate-Resistant
Acid Phosphatase (TRAP) Activity Proﬁles. The serum alka-
line phosphatase (AP) activity proﬁle of rats of control,
HFD, and HFD + BTE supplemented groups are shown
in Table 2. Rats of HFD-fed group (Group B) showed a
signiﬁcant increase in serum alkaline phosphatase activity
when compared to animals of control group (P<. 01)
(Group A). This increase in AP activity was signiﬁcantly
lowered (P<. 01) in rats receiving BTE (Group C). Likewise,
the signiﬁcant increase (P<. 01) in TRAP activity in HFD-
fed group (Group B), compared to control (Group A), could
be eﬀectively reduced by aqueous BTE supplementation
(Group C; Table 2).
3.3. Bone Density Proﬁles. Animals in the HFD-fed group
(Group B) had signiﬁcantly lower densities of the right
femur (P<. 01), eighth thoracic rib (P<. 01), eighth
t h o r a c i cv e r t e b r a( P<. 01), and fourth lumbar vertebra
(P<. 01), compared with the control group (Group A). BTE
supplementation could produce signiﬁcant increase (P<
.01) in bone density of all bones: right femur (P<. 01),
eighth thoracic rib (P<. 01), eighth thoracic vertebra (P<
.0 5 ) ,a n df o u r t hl u m b a rv e r t e b r a( P<. 01; Table 3).
3.4. Bone Tensile Strength. Figure 1 shows that compared
to control, bone tensile strength in HFD-fed animals was
signiﬁcantly reduced (P<. 01). BTE supplementation in
these animals was found eﬀective in recovering (P<. 01) this
tensile strength back to control group level.
3.5. Bone Calcium and Bone Phosphate Levels. Results of
bone calcium and phosphate levels are shown in Table 4.
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Figure 2: Serum estradiol level of control (CON; Group A), HFD
treated (Group B), and HFD + BTE (Group C) supplemented
female groups of rats. Values are expressed as mean ± S.E.M.
(n = 6, female data only). ###P<. 001 denotes signiﬁcance level
based on Kruskal-Wallis nonparametric ANOVA test and ∗∗P<. 01
denotes signiﬁcance level based on Mann-Whitney “U” multiple
comparison test.
Animals of HFD-fed group (Group B), compared to control
group (Group A), showed a marked decrease in calcium and
phosphatelevelsofrightfemur(calcium:P<. 01;phosphate:
P<. 01), eighth thoracic rib (calcium: P<. 01; phosphate:
P<. 01), eighth thoracic vertebra (calcium: P<. 01;
phosphate: P<. 01), and fourth lumbar vertebra (calcium:
P<. 01; phosphate: P<. 01). When these HFD-fed animals
weresupplementedwithBTE(GroupC),signiﬁcantrecovery
in content of both minerals was seen.
3.6. Serum Estradiol Level. Figure 2 shows the eﬀects of
supplementationofBTEonserumestradiollevelofHFD,fed
rats. Compared to control (Group A), a signiﬁcant decrease
in estradiol level was seen in HFD-fed (Group B) animals6 Journal of Osteoporosis
Table 1: Urinary excretion of calcium, phosphate, creatinine, and calcium:creatinine (Ca:Cr) ratio in control (Group A), HFD (Group B)
and HFD + BTE (Group C) supplemented groups of rats.
Parameters Control High-fat High-fat + BTE Signiﬁcance level## Signiﬁcance level∗
(Group A) (Group B) (Group C) Gr. A versus Gr. B Gr. B versus Gr. C
Urinary calcium (mg/24h) 0.81 ±0.24 3.21 ±0.56 1.01 ±0.11 P<. 01 P<. 01 P<. 01
Urinary phosphate (mg/24h) 1.13 ±0.084 3.21 ±0.085 1.32 ±0.206 P<. 01 P<. 01 P<. 01
Urinary creatinine (mg/24h) 0.45 ±0.16 0.97 ±0.021 0.65 ±0.09 P<. 01 P<. 01 P<. 01
Ca:Cr 1.132 ±0.16 3.37 ±0.54 1.48 ±0.14 P<. 01 P<. 01 P<. 01
Values are expressed as mean ± S.E.M. (n = 6). ##Denotes signiﬁcance level based on Kruskal-Wallis nonparametric ANOVA test and ∗ denotes signiﬁcance
level based on Mann-Whitney “U” multiple comparison test.
Table 2: Serum alkaline phosphatase (AP) activity and serum tartrate-resistant acid phosphatase (TRAP) activity in control (Group A),
HFD (Group B) and HFD + BTE (Group C) supplemented groups of rats.
Serum enzyme activity Control High-fat High-fat + BTE Signiﬁcance level## Signiﬁcance level∗
(Group A) (Group B) (Group C) Gr. A versus Gr. B Gr. B versus Gr. C
Alkaline phosphatase (U/L) 9.41 ±0.22 16.48 ±3.29 .97 ±0.24 P<. 01 P<. 01 P<. 01
TRAP (U/L) 2.1 ±0.32 4.29 ±0.26 2.04 ±0.28 P<. 01 P<. 01 P<. 01
Values are expressed as mean ± S.E.M. (n = 6). ##Denotes signiﬁcance level based on Kruskal-Wallis nonparametric ANOVA test and ∗ denotes signiﬁcance
level based on Mann-Whitney “U” multiple comparison test.
Table 3: Density of femur, eighth thoracic rib, eighth thoracic vertebra, and fourth lumbar vertebra in control group (Group A), HFD group
(Group B), and HFD + BTE supplemented group (Group C) of rats.
Parameters Control High-fat High-fat + BTE Signiﬁcance level## Signiﬁcance level∗
(Group A) (Group B) (Group C) Gr. A versus Gr. B Gr. B versus Gr. C
Bone density (gm/cm3)
Right femur 1.39 ±0.02 1.22 ±0.01 1.34 ±0.007 P<. 01 P<. 01 P<. 01
Eighth Thoracic Rib 2.57 ±0.28 1.44 ±0.03 2.15 ± 0.11 P<. 01 P<. 01 P<. 01
Eighth Thoracic Vertebra 1.33 ±0.03 1.23 ±0.02 1.299 ±0.01 P<. 05 P<. 05 P<. 01
Fourth Lumbar Vertebra 1.272 ±0.28 1.44 ±0.03 2.15 ± 0.11 P<. 01 P<. 01 P<. 01
Values are expressed as mean ± S.E.M. (n = 6). ##Denotes signiﬁcance level based on Kruskal-Wallis nonparametric ANOVA test and ∗ denotes signiﬁcance
level based on Mann-Whitney “U” multiple comparison test.
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Figure 3:(a)SerumRANKLactivityand(b)OPGlevelofcontrol(CON;GroupA),HFDtreated(GroupB),andHFD+BTEsupplemented
(Group C) groups of rats. Values are expressed as mean ± S.E.M. (n = 6). ###P<. 001 denotes signiﬁcance level based on Kruskal-Wallis
nonparametric ANOVA test, ##P<. 01 denotes signiﬁcance level based on Kruskal-Wallis nonparametric ANOVA test, ∗∗P<. 001 denotes
signiﬁcance level based on Mann-Whitney “U” multiple comparison test, and ∗P<. 05 denotes signiﬁcance level based on Mann-Whitney
“U” multiple comparison test.Journal of Osteoporosis 7
Table 4: Bone mineral content of femur, eighth thoracic rib, eighth thoracic vertebra and fourth lumbar vertebra in control group (Group
A), HFD group (Group B), and HFD + BTE supplemented groups (Group C) of rats.
Parameters Control High-fat High-fat + BTE Signiﬁcance level## Signiﬁcance level∗
(Group A) (Group B) (Group C) Gr. A versus Gr. B Gr. B versus Gr. C
Bone calcium (% of ash weight)
Femur 19.39 ±1.09 9.73 ±0.53 13.75 ±0.64 P<. 001 P<. 01 P<. 01
Eighth thoracic rib 23.39 ±0.84 15.49 ±0.92 23.01 ±1.38 P<. 01 P<. 01 P<. 01
Eighth thoracic vertebra 24.3 ±1.39 13.7 ±0.72 1 .52 ±1.02 P<. 01 P<. 01 P<. 01
Fourth lumbar vertebra 25.68 ±0.57 13.65 ±0.78 18.56 ±0.8 P<. 001 P<. 01 P<. 01
Bone phosphate (% of ash Weight)
Femur 8.6 ±0.49 3.88 ±0.46 7.81 ±0.62 P<. 01 P<. 01 P<. 01
Eighth thoracic rib 11.89 ±0.11 6.24 ±0.45 11.67 ±0.16 P<. 01 P<. 01 P<. 01
Eighth thoracic vertebra 10.67 ±0.36 7.21 ±0.23 10.72 ±0.43 P<. 01 P<. 01 P<. 01
Fourth lumbar vertebra 11.38 ±0.39 5.34 ±0.28 11.56 ±0.12 P<. 01 P<. 01 P<. 01
Values are expressed as mean ± S.E.M (n = 6). ##denotes signiﬁcance level based on Kruskal-Wallis nonparametric ANOVA test and ∗ denotes signiﬁcance
level based on Mann-Whitney “U” multiple comparison test.
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Figure 4: Transference of calcium in duodenal, jejunal, and ileal
segments of control (CON; Group A), HFD treated (Group B), and
HFD + BTE supplemented (Group C) groups of rats. Values are
expressed as mean ± S.E.M. (n = 6). ### and ## denote signiﬁcance
level P<. 001 and P<. 01, respectively, based on Kruskal-Wallis
nonparametricANOVAtestand ∗∗P<. 01denotessigniﬁcancelevel
based on Mann-Whitney “U” multiple comparison test.
(P<. 01). This could be recovered signiﬁcantly (P<. 01)
when BTE was supplemented (Group C).
3.7.SerumRANKLandOPGActivity. Figure 3depictsserum
levels of RANKL (Figure 3(a)) and OPG (Figure 3(b))o f
diﬀerent groups of rats. Compared to control, HFD-fed rats
showed a decrease in serum OPG (P<. 01) level, which
was found signiﬁcantly (P<. 05) counter regulated on BTE
supplementation. In contrast, compared to control, serum
RANKL level was increased signiﬁcantly (P<. 01) in HFD-
fed animals. On BTE supplementation, a signiﬁcant decrease
(P<. 01) in the RANKL level was noted.
3.8. Intestinal Transference of Calcium. Results in Figure 4
depicts that, compared to control, HFD-fed rats (Group B)
showed a segment-wise reduction in intestinal transference
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Figure 5: Ca2+-ATPase activity of intestinal mucosal extracts in
duodenal, jejunal, and ileal segments of control (CON; Group A),
HFD treated (Group B), and HFD + BTE supplemented (Group
C) groups of rats. Values are expressed as mean ± S.E.M. (n =
6). ##P<. 01 denotes signiﬁcance level based on Kruskal-Wallis
nonparametricANOVAtestand ∗∗P<. 01denotessigniﬁcancelevel
based on Mann-Whitney “U” multiple comparison test.
of calcium (P<. 01 for duodenum, jejunum, and ileum).
BTE supplementation could signiﬁcantly correct such alter-
ations in calcium transference in HFD-fed rats (P<. 01 for
duodenum, jejunum, and ileum).
3.9. Calcium ATPase Activity. Figure 5 shows the eﬀects of
feeding of HFD on the mucosal calcium ATPase activity
of diﬀerent segments of small intestine of rats. Results
show that, compared to control rats, HFD feeding caused a
signiﬁcant reduction in the activity of this enzyme (P<. 01
for duodenum, jejunum, and ileum), while BTE supplemen-
tation could signiﬁcantly increase this enzyme activity (P<
.01 for duodenum, jejunum, and ileum).
3.10. Intestinal Alkaline Phosphatase Activity. Figure 6
depicts that, compared to control group, HFD-fed rats8 Journal of Osteoporosis
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Figure 6: Alkaline phosphatase activity of intestinal mucosal
extracts in duodenal, jejunal, and ileal segments of control (CON;
Group A), HFD treated (Group B), and HFD + BTE supplemented
(Group C) groups of rats. Values are expressed as mean ± S.E.M.
(n = 6). ### and ## denote signiﬁcance level P<. 001 and P<. 01,
respectively, based on Kruskal-Wallis nonparametric ANOVA test
and ∗∗P<. 01 denotes signiﬁcance level based on Mann-Whitney
“U” multiple comparison test.
showed a signiﬁcant reduction in the activity of alkaline
phosphatase in all segments of small intestine (P<. 01 for
duodenum, jejunum, and ileum). BTE supplementation was
found signiﬁcantly eﬀective in restoring this enzyme activity
in all these segments (P<. 01 for duodenum, jejunum and
ileum).
3.11. Histological Analysis of Cancellous and Cortical Bones.
Histological studies of two diﬀerent types of bones were
conducted to determine the in vivo eﬀects of BTE in
the HFD-fed animals. HFD-fed rats (Group B) showed
a decrease in cortical thickness and empty bone marrow
space at the proximal tibia (Figures 7(a)–7(c))a n df o u r t h
lumbar vertebra (Figures 7(d)–7(f)), as compared to control
(Group A). Additionally, there was a decrease in trabecular
bone volume and thickness at the fourth lumbar vertebra.
However, on BTE supplementation, bone repairing actions
were seen in these HFD-fed animals.
4. Discussion
The present study examined the chemoprotective actions
of aqueous black tea extract (BTE) against HFD fed
(60%) NASH skeletal changes. Bone manifestations are
well-known as extrahepatic complications of chronic liver
disease. Patients with chronic liver disease are at increased
risk of developing hepatic osteodystrophy manifested as
osteomalacia or osteoporosis [56]. Osteoporosis is a frequent
complication of end-stage liver disease irrespective of its
etiology [57].
Recent research also suggests that there is a strong pos-
itive correlation between osteoporosis and hyperlipidemia.
Excess lipid consumption may lead to lipid accumulation
and subsequent oxidation within bone vasculature, wherein
osteoblastic diﬀerentiation may be altered. In addition to
their inhibitory role in osteoblastic diﬀerentiation, it is
believed that because oxidized lipids induce endothelial
expression of monocyte chemotactic factors, as well as other
potentinducersofosteoclasticdiﬀerentiation,oxidizedlipids
may also promote bone resorption [58].
Biochemical markers of bone turnover have been widely
used as research tool to measure the eﬀects of drugs on
bone remodeling [59]. Elevated levels of bone markers are
associated with rapid bone loss and may predict a greater
risk of fracture independently of bone mineral density
(BMD) variability [10]. In our study, compared to control,
HFD treated rats showed an increase in urinary loss of
calcium, phosphate, and creatinine (Table 1), which could be
signiﬁcantly corrected by BTE supplementation, suggesting
BTE possibly has some positive role in preventing bone
resorption and/or increase bone formation or both.
Results of studies of two other speciﬁc markers of bone
turnover, namely, urinary calcium-to-creatinine (Ca:Cr)
ratio and serum alkaline phosphatase (AP) further support
our speculation (Tables 1 and 2, resp.). It was observed
that BTE was eﬀective in reducing HFD-induced increase
in serum AP and urinary Ca:Cr ratio. Since a rise in AP
and Ca:Cr ratio has been linked with collagen degradation,
bone resorption and osteoporosis [60–63], it appeared that
BTE was possibly eﬀective in preventing bone loss. A close
association of increased serum concentrations of TRAP as
a potential index for osteoclastic activity is well established
[64]. In the present study, compared to control, HFD-fed
animals showed an increase in serum TRAP level (Table 2).
However, this response was found well regulated by BTE
supplementation, indicating that BTE possibly was eﬀective
even in controlling osteoclastic activity to preserve skeletal
health.
Such speculations were cross-examined in our studies by
measuring parameters like bone density (Table 3) and bone
mineral content (Table 4). Rats in the HFD fed-group had
signiﬁcantly lower bone densities and mineral content, com-
pared to control rats, which could be signiﬁcantly regained
by BTE supplementation, suggesting again the protective
role of BTE against HFD-fed skeletal dysfunctional changes.
Further conﬁrmatory evidence in favor of our speculation
was obtained in our experiment for bone tensile strength
or breaking force, which is required to break the bone.
Comparedtocontrol,HFD-fedanimalsshowedlowertensile
strength (Figure 1), which could be signiﬁcantly elevated
(increase in breaking force) on BTE supplementation.
Chronic liver disease accelerates the development of
hypogonadism due to both reduced hypothalamic release
of gonadotrophins and primary gonadal failure. A decline
in circulating estrogen may be a mediator of bone loss in
women and men with chronic liver disease [10]. In the
present study, HFD-fed female rats showed a signiﬁcant
decrease in serum estradiol level (Figure 2), which could be
considerably restored by BTE supplementation. This result
showed that BTE has eﬃcacy as a potent phytoestrogenic
compound. The estrogen-enhancing property of ﬂavonoids
[65, 66] from various extragonadal sites like mesenchymal
cells of adipose tissue, osteoblasts, and chondriocytes of
bone, numerous sites in the brain, breast, and vasculatureJournal of Osteoporosis 9
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Figure 7: Histological analysis of tibia ((a)–(c)) and lumbar vertebra ((d)–(f)) of rats (hematoxylin-eosin staining, X 100). Representative
photomicrograph from HFD group (b) with reduction in cortical thickness and empty bone marrow of the tibia than CON (a) and HFD +
BTE(c).PhotomicrographoflumbarvertebraofHFDgroup(e)withreductionincorticalthickness,emptybonemarrowandlesstrabecular
bonecomparedwithCON(d)andHFD+BTEgroup(f).Blueline,corticalthickness;bluestar,bonemarrow;redstar,emptybonemarrow;
black star, trabecular thickness.
[67, 68] possibly was responsible for such an increase in
serum estradiol level by modulating the aromatase activity
[68].
Osteoprotegerin (OPG) is a novel receptor that blocks
osteoclast formation. Either in a cell membrane-bound or
i nas o l u b l ef o r m ,R A N K L ,r e c e p t o ra c t i v a t o ro fN F - k a p p aβ
(RANK), stimulates osteoclastogenesis and osteoclastic bone
resorption. Factors that stimulate bone resorption increase
RANKLexpressionand,withsomeexceptions,decreaseOPG
expression [69]. In the present study, animals of HFD-fed
group showed a signiﬁcant decrease in serum level of OPG
(Figure 3(b)) and a signiﬁcant increase in serum level of
RANKL (Figure 3(a)), compared to control group of rats.
BTE supplementation, however, could signiﬁcantly restore
altered levels of serum OPG and RANKL, suggesting a
moreconﬁrmatoryprotectiveroleofBTEagainstosteoclastic
diﬀerentiation and activity in HFD-fed rats.
Calcium absorption has been reported to occur in
body throughout the length of the small intestine, the
absorption being greater in the duodenum and proximal
jejunum than in the ileum [70]. The involvement of two
intestinal enzymes, alkaline phosphatase, and Ca2+-ATPase,
has been proposed frequently in this phenomenon because
the activity of these enzymes correlates with the degree
of calcium absorption in diﬀerent parts of intestinal tract
under diﬀerent circumstances [50, 71, 72]. Results also
indicate that Ca2+-induced ATP hydrolysis in the intestine
is the result of two enzymatic activities, namely, alkaline
phosphatase present in brush border as well as basolateral
membranes and a more speciﬁc Ca2+-ATPase exclusively
located in basolateral plasma membrane [73]. Evidence
further indicates that estrogen is more directly involved in
determiningintestinalcalciumabsorptionbecausedecreased
calcium absorption due to ovarian hormone insuﬃciency is
corrected by hormone replacement therapy [74, 75]. In the
present study, intestinal transference of Ca2+ was reduced in
HFD-fed rats. Result indicated that deﬁciency of estrogen
had a negative inﬂuence upon intestinal transference of
calcium,astheseanimalsshowedagreaterdegree ofdecrease
in the transference of calcium than the control animals
(Figure 4). Such observation ﬁnds its support from earlier
ﬁndings that estrogen may have direct role via the estrogen
receptors in regulating intestinal calcium absorption in vitro
and in vivo [76, 77]. BTE supplementation in the present
study was found eﬀective in correcting such reduction in
calcium transference, indicating that BTE also possibly had
positive inﬂuence upon mucosal transference of calcium.10 Journal of Osteoporosis
To ascertain the mechanism of such decrease in intestinal
transference of calcium, the activities of two most relevant
mucosal calcium transferring enzymes, namely, alkaline
phosphatase and calcium-ATPase were examined. Activities
of both of these enzymes were found inhibited in HFD-
fed group of animals (Figures 5 and 6). This supports well
the earlier observations that both the enzymes are involved
in calcium absorption as the activities of these enzymes
correlate with the degree of calcium absorption in diﬀerent
partsoftheintestinaltractunderdiﬀerentcircumstances[50,
71,72].BTEsupplementationcouldwellrestoretheactivities
ofbothoftheseenzymesindicatingthattheobservedpositive
inﬂuence of BTE upon intestinal transference of calcium
is thus mediated through modulation of activities of these
transferring enzymes.
Histological (Figure 7) observation of serial section of
tibia and lumbar vertebrae revealed that, compared to
control, signiﬁcant reduction in cortical thickness and
bone marrow content was seen in HFD fed rats. On BTE
administration, these changes were signiﬁcantly corrected,
suggesting a potential bone repairing action of BTE.
It is recognized that animal studies contain some inher-
ent design limitations. First, restrictions of animal use and
therefore sample size; second, the doses required for demon-
strating the disease prevention eﬀects are usually higher than
the amounts consumed by humans. Furthermore, because
of infrastructure limitations it was necessary to rely on
biochemicalandhistologicalmeasuresratherthanusingpeer
reviewed DEXA-derived indices for examining bone proﬁles.
To minimize the error associated with such limitations, we
took extreme care while selecting the parameters, collecting
data and analyzing them by well-recognized statistical meth-
o d sf o l l o w e db yu s[ 34, 35] earlier.
5. Conclusions
In conclusion, results of this study strongly suggest a
protective role of BTE against NASH-induced changes in
bone metabolism in rats.
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